KRAS/BRAF Analysis in Ovarian Low-Grade Serous Carcinoma Having Synchronous All Pathological Precursor Regions.
KRAS/BRAF Analysis in Ovarian Low-Grade Serous Carcinoma Having Synchronous All Pathological Precursor Regions.
复制标题
DOI：
10.3390/ijms17050625
复制
发表时间：
2016-04-26
影响因子：
5.6
通讯作者：
Kyo S
中科院分区：
文献类型：
--
作者：
Nakamura K;Nakayama K;Ishibashi T;Ishikawa N;Ishikawa M;Katagiri H;Minamoto T;Sato E;Sanuki K;Yamashita H;Iida K;Sultana R;Kyo S
卵巢低度恶性浆液性癌被认为开始为浆液性囊腺瘤或腺纤维瘤，以缓慢的逐步方式进展。在低级别浆液性癌中，KRAS或BRAF基因的激活突变频率很高;然而，这些突变如何促进肿瘤进展仍不清楚。这是第一份报告，以跟踪组织病理学进展的浆液性腺纤维瘤，以低级别浆液性癌。通过病理学和分子遗传学方法对每个阶段进行单独分析，以确定不同进展阶段之间的差异。
Ovarian low-grade serous carcinoma is thought to begin as a serous cystadenoma or adenofibroma that progresses in a slow stepwise fashion. Among the low-grade serous carcinomas, there is a high frequency of activating mutations in the KRAS or BRAF genes; however, it remains unclear as to how these mutations contribute to tumor progression. This is the first report to track the histopathological progression of serous adenofibroma to low-grade serous carcinoma. Each stage was individually analyzed by pathological and molecular genetic methods to determine what differences occur between the distinct stages of progression.